← Back to Search

CAR T-cell Therapy

Gene-Modified T Cells for Advanced Cancers

Phase 1 & 2
Waitlist Available
Led By Philip McCarthy, MD
Research Sponsored by Roswell Park Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with solid tumors meeting specific criteria for inoperable or metastatic melanoma, ovarian, primary peritoneal or fallopian tube carcinoma, synovial sarcoma, or other histologies
Patients must have adequate venous access for apheresis
Must not have
Requirement for systemic corticosteroids or concurrent immunosuppressive drugs
Uncontrolled intercurrent illness
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 15 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing the side effects and best dose of gene-modified T cells, given with or without decitabine, to treat patients with malignancies expressing cancer-testis antigens 1 (NY-ESO-1) gene that have spread to other places in the body (advanced).

Who is the study for?
This trial is for patients with advanced cancers like melanoma, ovarian, peritoneal or fallopian tube carcinoma, and synovial sarcoma that express the NY-ESO-1 gene. Participants need available tissue for testing or agree to a biopsy, have a caregiver nearby, meet medical criteria, use birth control, understand the study's nature and consent to it. They must not have brain metastases or severe autoimmune diseases.
What is being tested?
The trial tests gene-modified T cells with/without decitabine in treating advanced malignancies expressing NY-ESO-1. It aims to find out how well these treatments work and their best doses by modifying patients' T cells to target tumor cells better.
What are the potential side effects?
Potential side effects include immune reactions due to modified T cells targeting cancerous tissues; chemotherapy-related issues such as fatigue, nausea; risk of infection; possible adverse reaction from decitabine including blood disorders.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer is inoperable or has spread and falls into one of the specified categories.
Select...
My veins are suitable for apheresis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently taking steroids or drugs that affect my immune system.
Select...
I do not have any unmanaged ongoing illnesses.
Select...
I currently have an active infection.
Select...
I have active brain tumors.
Select...
I do not have dementia or significant changes in my mental status.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 15 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 15 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Dose Limiting Toxicities
Number of Participants With Feasibility Concerns in Manufacturing of NY-ESO-1/ dnTGFbetaRII Engineered Cells
Secondary study objectives
Expression of the NY-ESO-1 T Cell Receptor (TCR) Transgenic Protein in Peripheral Blood Mononuclear Cells (PBMC)
Replication Competent Retrovirus (RCR)
Tumor Response (Complete and Partial Response)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)Experimental Treatment5 Interventions
Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
Group II: Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)Experimental Treatment4 Interventions
Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Decitabine
2004
Completed Phase 3
~1680
Cyclophosphamide
2010
Completed Phase 4
~2310
Leukapheresis
2016
Completed Phase 2
~710

Find a Location

Who is running the clinical trial?

Roswell Park Cancer InstituteLead Sponsor
410 Previous Clinical Trials
32,433 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,886 Previous Clinical Trials
41,020,922 Total Patients Enrolled
Philip McCarthy, MDPrincipal InvestigatorRoswell Park Cancer Institute
1 Previous Clinical Trials
31 Total Patients Enrolled

Media Library

Gene-Modified T Cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02650986 — Phase 1 & 2
Cancer Research Study Groups: Cohort I (cyclophosphamide, TCR/dnTGFbetaRII), Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)
Cancer Clinical Trial 2023: Gene-Modified T Cells Highlights & Side Effects. Trial Name: NCT02650986 — Phase 1 & 2
Gene-Modified T Cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02650986 — Phase 1 & 2
~2 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top